If you are unable to participate during the live event, a replay
of the webcast will be available for a limited time at http://www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop
novel drugs for its product pipeline and for its partners. The
Company has successfully commercialized the world's first antisense
drug and has 17 drugs in development. Isis' drug development
programs are focused on treating cardiovascular and metabolic
diseases. Isis' partners are developing drugs for a wide variety of
diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is
developing and commercializing the Ibis T5000(TM) Biosensor System,
a revolutionary system to identify infectious organisms. As an
innovator in RNA-based drug discovery and development, Isis is the
owner or exclusive licensee of over 1,500 issued patents worldwide.
Additional information about Isis is available at http://www.isispharm.com.